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The human and veterinary disease complex known as African trypanosomiasis continues to inflict significant global morbidity,
mortality, and economic hardship. Drug resistance and toxic side effects of old drugs call for novel and unorthodox strategies for
new and safe treatment options. We designedmethyltriazenyl purine prodrugs to be rapidly and selectively internalized by the
parasite, after which they disintegrate into a nontoxic and naturally occurring purine nucleobase, a simple triazene-stabilizing
group, and the active toxin: a methyldiazonium cation capable of damaging DNA by alkylation. We identified 2-(3-acetyl-3-
methyltriazen-1-yl)-6-hydroxypurine (compound 1) as a new lead compound, which showed submicromolar potency against
Trypanosoma brucei, with a selectivity index of>500, and it demonstrated a curative effect in animal models of acute trypanoso-
miasis. We investigated the mechanism of action of this lead compound and showed that this molecule has significantly higher
affinity for parasites over mammalian nucleobase transporters, and it does not show cross-resistance with current first-line
drugs. Once selectively accumulated inside the parasite, the prodrug releases a DNA-damaging methyldiazonium cation.We
propose that ensuing futile cycles of attempted mismatch repair then lead to G2/M phase arrest and eventually cell death, as evi-
denced by the reduced efficacy of this purine analog against a mismatch repair-deficient (MSH2/) trypanosome cell line. The
observed absence of genotoxicity, hepatotoxicity, and cytotoxicity against mammalian cells revitalizes the idea of pursuing para-
site-selective DNA alkylators as a safe chemotherapeutic option for the treatment of human and animal trypanosomiasis.
African trypanosomiasis covers a complex of diseases in hu-mans (sleeping sickness), cattle (nagana), camels (surra),
horses (dourine), other livestock, and in wild and companion an-
imals (1). Transmission of the human disease is entirely limited to
the habitat of the tsetse fly vector in sub-Saharan Africa and is
caused by two subspecies of Trypanosoma brucei: T. brucei gam-
biense inWest and Central Africa, andT. brucei rhodesiense in East
and southern Africa. T. brucei rhodesiense is a well-known zoono-
sis, and several other species, including T. brucei brucei, Trypano-
soma congolense, Trypanosoma equiperdum, Trypanosoma evansi,
and Trypanosoma vivax, give rise to a range of animal pathologies.
As T. equiperdum, T. evansii, and T. vivax do not require tsetse fly
transmission, these infections have spread to other regions, in-
cluding theMiddle East, southern Asia, and South America (2, 3).
Virtually the only method of control for human African
trypanosomiasis is treatment with chemotherapy, but the few
drugs available are old, often toxic, and threatened by resistance
(4). Due to the introduction of nifurtimox-eflornithine combina-
tion therapy (NECT) for late-stage T. brucei gambiense human
African trypanosomiasis (HAT), melarsoprol usage is finally be-
ing phased out in much of central Africa, but NECT is expensive
and relies on a large number of intravenous infusions (5). For
animal trypanosomiasis, the situation is almost as bad, with a few
50-year-old drugs for which resistance has been reported
throughout Africa (4, 6). As there is no realistic prospect of a
vaccine against any of the African Trypanosoma species, it follows
that new drugs for African trypanosomiasis are urgently required.
A few compounds are proceeding toward (pre)clinical test stages
(7), but the success of these compounds is by no means ensured.
In addition, since trypanosomiasis is a highly complex set of con-
ditions of numerous infective species, hosts, and disease stages, it
is highly unlikely that a single new compound can meet all the
diverse needs. However, it is possible to demand that new
trypanocides, in order to be of value, have lower toxicity than that
of the current drugs, and, crucially, must be active against strains
resistant to the current therapies, particularly diamidines and
melaminophenyl arsenicals. The mechanisms of resistance and
cross-resistance to and between these drugs have intensively been
studied in the last decade, particularly in the model organism T.
brucei brucei (8, 9). The activity and resistance of these trypanocides
depend on a set of transport proteins that mediate their uptake into
the trypanosomes: the aminopurine transporter P2/TbAT1 (10), the
high-affinity pentamidine transporter 1 (HAPT1), encoded by aqua-
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glyceroporin 2 (11, 12), and the low-affinity pentamidine transporter
(LAPT1) (13).
The variousdiamidines and arsenicals are transported todifferent
extents and with very different affinities by each of the three known
drug transporters, explaining the complicated cross-resistance pat-
terns (8).
Thus, dependence on one or more of the known drug trans-
porters would almost certainly result in cross-resistance with ex-
isting chemotherapeutic agents. Yet, selective trypanocidal action
is most commonly achieved through selective uptake, exploiting
the extensive, unique, and highly efficient collection of trans-
porter proteins of the trypanosome (14, 15). We therefore sought
to rationally exploit a different set of high-affinity trypanosomal
transporters, thereby ensuring rapid and selective accumulation
of the agent within its target cell without building in cross-resis-
tance to existing chemotherapy. The purine nucleobase transport-
ers are perfectly suited for drug delivery, in that multiple variants
of these transporters are expressed in trypanosomes, with overlap-
ping substrate selectivities and much higher substrate affinities
than those of their mammalian orthologues (16). In addition, T.
brucei nucleobase transporters are proton symporters, meaning that
they utilize the proton motive force across the plasma membrane to
actively transport their substrate into the cell, even against a strong
concentration gradient (17, 18). All this has the effect of rapidly and
selectively pumping the active compound into the target cell and, as
active transport is monodirectional, the substrate will not be able to
egress from the cell in the same way (14).
The active toxophore to be carried through the nucleobase
transporters, coupled to a nucleobase, must be in the right posi-
tion of the purine ring and must be small enough not to interfere
with translocation by the transporters. Here, we present the devel-
opment of purine derivatives that meet these requirements by
carrying a methyltriazenyl toxophore on the purine 2 position.
These methyltriazenyl purines (MTPs) constitute a class of highly
effective antitrypanosomal agents.We propose that this therapeu-
tic class of agents damages the DNA of the parasite, which results
in futile cycling of the mismatch repair system, leading eventually
to parasite cell death.
MATERIALS AND METHODS
Cells. Bloodstream-form T. brucei brucei strain 427 (BS221) (19), the
derived multidrug-resistant clonal lines tbat1/ (10) and MSH2/,
MSH2/ and MSH2// (20, 21), and human embryonic kidney cells
(HEK 293T) (22) were maintained and used for alamarBlue drug sensi-
tivity assays (23), as described previously (24). For HEK 293T cells, an
extended alamarBlue protocol was used, which was adapted from that
described previously (22). Briefly, in a 96-well microtiter plate, cells were
seeded at 30,000 cells in 100 l of Dulbecco’s modified Eagle’s medium
(DMEM) per well and allowed to adhere for 24 h. Serial drug dilutions
were then added (100 l per well), and after 30 h of incubation, alamar-
Blue reagent (20 l) was added, and the plate was read after another 24 h
of incubation. Assays for transport of [3H]hypoxanthine (at 0.05 M for
60 s, 28Ci/mmol; Amersham) by bloodstream-formT. brucei brucei strain
427 and for the transport of [2,8-3H]adenine (at 1Mfor 5 s, 24Ci/mmol;
PerkinElmer) by human red blood cells, obtained fromwhole-blood sam-
ples donated by healthy volunteers, was performed exactly as described
previously using a rapid oil-stop protocol (19). For scanning electron
microscopy, 2 106 drug-treated bloodstream-form T. brucei brucei cells
were washed twice with wash buffer (33 mM HEPES, 98 mM NaCl, 4.6
mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM
MgCl2, 23 mM NaHCO3, 14 mM glucose [pH 7.3]) and fixed with 2.5%
glutaraldehyde in 0.1M phosphate buffer (pH 7.4) for 1 h. The fixed cells
were washed four times with 0.1 M sodium phosphate (pH 7.4) and
placed on coverslips, which were immersed in osmium tetroxide (1%
[wt/vol]) in distilled water for 1 h and then rinsed twice in distilled
water. Samples were dehydrated through graded ethanol solutions,
dipped in hexamethyldisilazane (HMDS) for 30 s, and left in a desic-
cator overnight. Dried samples were gold conductive coated using a
sputter coater and viewed in a Philips 500 scanning electron micro-
scope (EM) at 6 kV.
DNA content and integrity. The DNA content of bloodstream-form
T. brucei brucei 427 treated with drugs was visualized by DAPI (4=,6-
diamidino-2-phenylindole) staining followed by microscopic analysis,
and by propidium iodide staining followed by flow cytometry, as de-
scribed previously (25). The occurrence of DNA strand breaks in blood-
stream-form T. brucei brucei 427 or HEK293T cells as a consequence of
drug treatment was monitored by flow cytometry using the APO-BrdU
TUNEL assay kit (catalog no. A23210; Life Technologies), according to
the manufacturer’s protocol.
In vivo trypanocidal assays. The experiments were performed es-
sentially as described previously (26). Female NMRI mice were in-
fected intraperitoneally (i.p.) with 104 bloodstream-form T. brucei bru-
cei (strain STIB 795) or 3  103 T. brucei rhodesiense (strain STIB 900).
Experimental groups of four mice were treated i.p. with test drug daily on
four consecutive days starting from day 3 postinfection. A control group
was infected but remained untreated. The tail blood of each mouse was
checked for parasitemia up to 60 days postinfection; mice were culled
when parasitemia was 108 trypanosomes/ml of blood. Surviving and
aparasitemic mice at day 60 were considered cured and were euthanized.
All protocols and procedures used in this study were reviewed and ap-
proved by the local veterinary authorities of the Canton Basel-Stadt, Swit-
zerland.
RESULTS
Rational design of methyltriazenyl purines for selective uptake
by T. brucei. In bloodstream form (BF), T. brucei purines are
primarily taken up via the broad-specificity hypoxanthine trans-
porters H2 and H3 (18). Substrate recognition models that we
previously published for this transporter class showed that the
purine 2-position is not utilized in binding to trypanosomatid
nucleobase transporters, whereas it is engaged in hydrogen bond
formation in human nucleobase transporters (19, 27). Substitu-
ents on the purine 6-position larger than the natural exocyclic
heteroatoms were shown to significantly reduce affinity for the
hypoxanthine H2 transporter (19). We therefore considered the
purine 2-position to bemost suitable for attaching a toxophore to
the purine skeleton for its selective delivery into the parasite. To
keep the size of the toxophore to a minimum, we opted for a
simple methyltriazene moiety. The methyltriazenyl toxophore is
spontaneously or enzymatically hydrolyzed in the body, causing
the release of reactive methyldiazonium ions (28), which are
known to cause fatal methylation of nucleobase moieties within
nucleic acids. Examples of methyltriazenyl prodrugs (MTPs) are
temozolomide and dacarbazine, which are used for the treatment
of malignancies, including glioblastoma and metastatic mela-
noma (29, 30). We generated MTP derivatives designed to disin-
tegrate by hydrolysis into three parts: (i) a purine nucleobase,
specifically, guanine or 2-aminoadenine; (ii) a simple triazene-
stabilizing group, such as a small carboxylic acid or an alcohol and
CO2; and (iii) a methyldiazonium ion (Fig. 1, see supplemental
material for synthetic details).
Methyltriazenyl purines have potent antitrypanosomal ac-
tivity.An assessment of the antitrypanosomal activity of a series of
MTPs (Table 1) identifiedMTP compound 1with promising sub-
micromolar potency against BF T. brucei in vitro (Fig. 2A). We
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found that the antitrypanosomal activity appeared to be affected
by two main determinants: (i) the nature of the toxophore-stabi-
lizing group that controls the rate of triazene hydrolysis, and (ii)
the nature of the functional group on the purine 6-position. In
general, 6-oxo MTPs appeared to have higher trypanocidal activ-
ity than that of 6-aminoMTPs,with the exception of compound4.
Among the 6-oxo MTPs, the most active compounds were those
with stabilizing electron-rich groups, such as acetamide (com-
pound 1), phenylurethane (compound 2), and ethylurethane
(compound 3), whereas compound 4, harboring a strongly elec-
tron-withdrawing p-nitrophenylurethane moiety, had practically
lost antitrypanosomal activity. The twomost potent 6-oxoMTPs,
compound 1 and its derivative, compound 2, have hydrolysis half-
lives of 6.8 0.4 h and 5.6 0.3 h, respectively, under physiolog-
ical conditions (see Fig. S1 in the supplemental material),
whereas p-nitrophenylurethanes, with hydrolysis half-lives in
the order of 20 min (31), are probably too unstable and likely
decompose before effective levels have been built up in the parasite.
Among the 6-amino MTPs, the same trend was observed, with the
derivative compound 6, containing an electron-rich toxophore-sta-
N
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FIG 1 Design of methyltriazenyl purine antitrypanosomal prodrugs releasing
methyldiazonium cations. Purine numbering is indicated.
TABLE 1 In vitro activity and transport parameters of trypanocidal methyltriazenyl purinesa
R1 R2 R3
1 CH3 CH3 OH
2 CH3 O OH
3 CH3 OCH2CH3 OH
4 CH3 O NO2 OH
5 H O OH
N
N NH
N
R3
N
N
N
R1
R2
O
R1 R2 R3
6 CH3 O NH2
7 CH3 O NO2 NH2
8 CH3 O
NH2
O
NH2
9 CH3 CH3
O
10 CH3 O
O
Compoundb
In vitro activity (EC50)
c Transport (Ki value)
d
T. brucei bruceiWT T. brucei brucei 427 tbat1/ HEK293 SI T. bruceiH2 hRBC FNT1
1 0.42 0.05 0.52 0.08 250 595 0.59 0.15 4.8 0.7 (0.05)e
2 0.80 0.07 1.21 0.19 250 312 0.20 0.06 3.0 1.1 (0.02)e
3 1.84 0.08 2.86 0.13 250 136 0.12 0.03
4 114 34 157 55 250 2 ND
5 100 100 250 0.09 0.02
6 10.4 0.5 10.7 0.4 100 24 0.46 0.08 1.2 0.18 (0.05)e
7 19.4 4.1 20.7 4.6 250 13 ND
8 81 28 100 250 3 0.13 0.08
9 ND ND ND 5.8 0.01
10 ND ND ND 22.5 9.2
Guanine 0.36 0.18f
Hypoxanthine 0.12 0.03f
Adenine 3.2 1.1f
DIM 0.26 0.05 7.9 0.7
PAO 0.94 0.34
a Data are in M and represent the mean standard error of mean (n 3).
b DIM, diminazene, an antitrypanosomal reference drug. PAO, phenylarsine oxide, a general cytotoxic control.
c T. brucei brucei 427 tbat1/ lacks the TbAT1 transporter and displays no P2 transport activity (10). WT, wild type; HEK293, human embryonic kidney 293T cells; SI, in vitro
selectivity index, calculated as EC50(HEK)/EC50(T. brucei bruceiWT); ND, not determined.
d T. bruceiH2, hypoxanthine transporter 2 of T. brucei brucei; hRBC FNT1, facilitative nucleobase transporter 1 of human red blood cells.
e Paired t test, measuring the significance of difference between T. brucei bruceiH2 and hRBC FNT1 transport.
f Numbers taken from reference 18.
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bilizing group, showing higher trypanocidal activity than those with
electron-withdrawing groups, such as compounds 7 and 8.
The higher trypanocidal activity of the 6-oxo derivative 2 ver-
sus the 6-amino derivative compound 6 may be partly due to
higher translocation rates as a result of the higher affinity that
6-oxopurines typically have for trypanosomal nucleobase trans-
porters (18, 19), resulting in an approximately 5-fold higher effi-
ciency of transport for hypoxanthine over adenine (32). However,
the 6-aminoMTPs 6 (Ki	 0.46M) and 8 (Ki	 0.13M) rather
surprisingly displayed a higher affinity for theH2 transporter than
adenine (Ki	 3.2 M), whereas the 2-position triazene substitu-
tion had made no significant change to the affinity of the 6-oxo
derivatives (Table 1). This observation suggests a slightly different
binding orientation for the 6-amino and 6-oxo derivatives, as pre-
viously reported for substrates of the UapA nucleobase trans-
porter of Aspergillus nidulans (33, 34). To assess potential cross-
resistance with the current first-line trypanocidal drugs, we tested
theMTPs against the drug-resistant clonal lineT. brucei brucei 427
tbat1/, lacking the TbAT1/P2 aminopurine transporter (10)
and thus displaying reduced sensitivity to diamidines and
melaminophenyl arsenicals (4). The antitrypanosomal activities
of theMTPswere not significantly different between thewild-type
and tbat1/ cell lines, although the diamidine diminazene dis-
played 30-fold lower activity against tbat1/ cells (Fig. 2A and
Table 1), indicating that cross-resistance with diamidines is not
likely to occur (10, 35). Furthermore, these purine derivatives
were not toxic to human embryonic kidney cells (HEK293T cells)
to themaximum concentration tested (250M; Table 1). MTPs 1
and 2 displayed promising selectivity indices of595 and312,
respectively. Control derivative compound 5, lackingmethylating
potential, did not show any toxic effects toward either trypano-
somes or HEK cells, as expected. DNA-damaging agents are po-
tentially mutagenic. However, an Ames test with compound 1 did
not reveal any mutagenic activity before or after metabolic activa-
tion with induced rat liver homogenate S9 (see Fig. S2 in the sup-
plemental material). Furthermore, compound 1 displayed no
hepatotoxic effects on mammalian primary hepatocytes (see Fig.
S3 in the supplemental material).
Methyltriazenyl purine 1 cures acute trypanosomiasis in vivo.
Lead compound 1 showed a 100% cure rate in a mouse model of
acute trypanosomiasis infection, in which eachmouse was treated
at 3 days postinfection by an intraperitoneal injection with 50
mg/kg of body weight of compound 1 for four consecutive days
(Fig. 2B). All treated mice were parasite free after treatment, sur-
vived 60 days, and were considered cured. In the acute model,
mice were infected with T. brucei brucei (STIB 795), which is
pathogenic for rodents but not for humans. In a more stringent
mouse model of trypanosomiasis, mice were infected with T. bru-
cei rhodesiense (STIB 900), which causes HAT in eastern Africa. In
this stringent model, treatment with 50 mg/kg compound 1 (i.p.)
for four consecutive days showed a 75% cure rate (see Fig. S4 in
the supplemental material).
Selective uptake of MTPs by trypanosomes. Having shown
that MTPs are not likely to be taken up by TbAT1/P2 transport
activity, we tested the affinity of MTPs for the H2 hypoxanthine
transporter in BF T. brucei. MTPs 1 to 8 displayed high affinity for
the H2 transporter, comparable to the affinities of the natural
substrates hypoxanthine and guanine (Table 1). In line with our
substrate recognition models (19), MTPs, such as compounds 1
and 2, lacking a 6-oxo substituent, showed higher affinity for the
H2 transporter than their synthetic precursors, compounds 9 and
10, respectively, which still carry an O6-benzyl substitution (Fig.
2C). This likely also explains the much lower antiprotozoal po-
tency exerted by the O6-benzyl-2-methyltriazenyl purines with
antitumor activity (see Fig. S5 in the supplemental material) (31),
consistent with the antiprotozoal activity being principally deter-
mined by effective uptake via the nucleobase transporters. Fur-
thermore, antitrypanosomal MTPs 1 and 2 (Fig. 2D) displayed
significantly higher affinity for the trypanosomal hypoxanthine
H2 transporter than that for the human facilitative nucleobase
transporter (FNT1) (Fig. 2D and Table 1), pointing to selective
uptake by the parasite.
The standard culture medium, HMI-9, used for T. brucei drug
sensitivity assays (but not for the hypoxanthine transport assays)
contains 1 mM hypoxanthine, which might interfere with uptake
of MTPs through hypoxanthine transporters during the 72 h of
incubation. We therefore retested the potency of compound 1 on
T. brucei grown in Creek’s minimal medium (36) in the presence
of either inosine (not a substrate of H2/H3 [18]) or hypoxanthine
as the purine source (see Fig. S6 in the supplementalmaterial).We
found that the sensitivity of bloodstream-form T. brucei to com-
pound 1 was indeed higher in a medium with inosine as the only
purine source, compared to the same medium containing the
same concentration of hypoxanthine (P  0.02). The 50% effec-
tive concentrations (EC50s) for several reference drugs (pentami-
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FIG 2 Methyltriazenyl purines demonstrate potent antitrypanosomal activ-
ity. (a) Dose-response curves for compound 1, compound 5 (a control lacking
alkylating activity), and reference drug diminazene (DIM). Wild-type 427
(WT)BFT. brucei cells are comparedwith drug-resistant tbat1/ cells lacking
the P2 purine transporter (knockout [KO]). The results from one representa-
tive experiment are shown from aminimum of 3 independent determinations
(b) MTP compound 1 cures acute trypanosomiasis in vivo. Kaplan-Meier sur-
vival plot for female NMRI mice (n 	 4 per group) after infection with T.
brucei brucei (STIB 795) (inoculum, 1 104 parasites). Intraperitoneal injec-
tionwith compound 1 started 3 days after infection at a single dose of 50mg/kg
per day for 4 days. (c) Inhibition of the uptake of 0.05 M [3H]hypoxanthine
in BF T. brucei cells by the indicated purine analogs. (d) Inhibition of 1 M
[3H]adenine uptake in red blood cells by compounds 1 (black squares) and 2
(red triangles). (c and d) Data are the average and standard error of the mean
(SEM) of triplicate determinations from one experiment performed in tripli-
cate; each experimentwas performed fully independently3 timeswith highly
similar outcomes. Average values for inhibition constants (Ki) are given in
Table 1.
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dine, suramin, and phenylarsine oxide) were not significantly
different for the two purine sources. These observations are con-
sistent with most of the uptake of compound 1 being mediated by
hypoxanthine-sensitive transporters.
Methyltriazenyl purine 1 causes cell cycle arrest in trypano-
somes. Given its promising antiparasitic efficacy in vitro and in
vivo, we selected lead compound 1 for further antitrypanosomal
mechanism-of-action studies. A culture of BFT. brucei exposed to
compound 1 was arrested in its proliferation (Fig. 3A). We ana-
lyzed the DNA content of these cells over 24 h by flow cytometry
(Fig. 3B; see also Fig. S7 in the supplemental material). After 4 h of
exposure to 15 M compound 1, we observed a decrease in the
proportion of cells with normal diploid (2C) DNA content,
whereas an aberrant population of cells started to appear with a
DNA content between 2C and 4C. After 24 h, this trend culmi-
nated in themajority of cells having an apparent 4CDNA content,
indicating an inability to finish cell division after apparently com-
pleting DNA synthesis. We also monitored the karyotype distri-
bution of BF T. brucei over time (see Fig. S8 in the supplemental
material), using DAPI staining to visualize nuclei (N) and kineto-
plasts (K). Within the first 8 h (the normal time to complete one
cell cycle) of exposure to compound 1, we observed a significant
increase in 1N2K cells, with a coincident decrease in 1N1K and
2N2K. After this time, the proportion of cells with 1N2K dropped,
with a coincident increase in the proportion of cells having mul-
tiple kinetoplasts (1N3K, 1N4K increasing up to 1N8K). In the
multikinetoplast cells, the nucleus was usually considerably en-
larged and often bilobed, and cells typically showed aberrantmor-
phology (Fig. 3C). Scanning electron microscopic (EM) analysis
of cells treated with compound 1 showed that the aberrant cells
grewmultiple new flagella, accompanied by the ingression of var-
ious cleavage furrows (Fig. 3D). These results suggest that the cells
are unable to complete nuclear division but do proceed with kin-
etoplast division independently, and cytokinesis does not occur.
The absence of cytokinesis does not prevent kinetoplast replica-
tion and segregation or outgrowth of a new flagellum, which in-
dicates that compound 1 predominantly affects replication and
segregation of nuclear DNA.
Mismatch repair is implicated in the mechanism of action.
The cytostatic activity of anticancer diazomethane-releasing
drugs, such as temozolomide and dacarbazine, is based on O6-
guanine methylation and a consequent futile cycling of the DNA
mismatch repair system (MMR), which ultimately results in DNA
strand breaks and cell death by apoptosis (37). TheMMRdoes not
repair the O6-methylated guanine residue itself, but it is rather
trying to correct the nucleotide that is base paired to it on the
newly synthesized strand, and it thereby drives a futile cycle of
repetitive nonproductive repair. To assess whether MTP treat-
ment leads to DNA strand breaks in T. brucei, we performed a
terminal deoxynucleotidyltransferase-mediated dUTP-biotin
nick end labeling (TUNEL) assay, monitoring 5-bromo-2-de-
oxyuridine 5-triphosphate (BrdUTP) incorporation visualized by
a fluorescein isothiocyanate (FITC)-labeled anti-BrdU antibody.
Treatment of BF T. brucei with just 3 M compound 1 for 24 h
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resulted in a 2-fold increase in BrdU incorporation, indicating
that compound 1 induces DNA strand breaks (Fig. 4A). In con-
trast, exposure of human HEK cells to a much higher concentra-
tion of compound 1 (200 M) for 24 h revealed no increase in
BrdU incorporation relative to that of the controls, and thus no
DNA strand breaks were induced (Fig. 4B).
Methyltriazenyl prodrugs releasemethyldiazonium species ca-
pable of methylating nucleobases by an SN1-type nucleophilic
substitutionmechanism, transferring the carbonium ion CH3
 to
electron-rich centers, such as the exocyclic oxygen or nitrogen
atoms of DNA bases (37). While SN1-type alkylators are MMR
dependent, SN2-type alkylators (such as MMS and phleomycin)
are not, as SN2-type alkylators predominantly target purine ring
nitrogen atoms and generate double-strand breaks through base
excision repair-mediated processing (38). Reduced expression or
impairment of the MMR has been shown to confer resistance to
DNA-alkylating agents of the SN1 type but not to those of the SN2
type (39, 40). The MMRmachinery is well conserved throughout
evolution, and trypanosomatids also have a functional MMR sys-
tem (20, 21). The nuclear proteinMSH2 is a central component of
the eukaryotic MMR, and its inactivation leads to a loss of
MMR function (41). In T. brucei, MSH2 mutants lacking one
(MSH2/) or two (MSH2/) alleles were shown to be increas-
ingly tolerant to DNA damage induced by the SN1-type alkylator
N-methyl-N=-nitro-N-nitrosoguanidine (MNNG) (20, 21). We
tested the toxicity of selectedMTPs against fourT. brucei cell lines,
MSH2/ (wild-type), MSH2/ (single knockout), MSH2/
(double knockout), andMSH2// (reexpressing [20]) cells and
compared their activities to those of various reference SN1 and SN2
type alkylators. As expected, only SN1-type alkylators, theMTPs 1
and 2, temozolomide and MNNG, showed reduced potency
against cells with impaired or lost MSH2 activity (see Table S1 in
the supplemental material). Like MNNG, MTP 1 became signifi-
cantly less effective against cells that have no MSH2 activity (P
0.02 and 0.01 for single- and double-knockout cells, respec-
tively) (Fig. 4C). Reintroduction of the MSH2 gene reversed the
decreased sensitivity. This indicated that the antitrypanosomal ac-
tivity of compound 1 is, at least in part, mediated through base
modifications recognized by the MMR machinery that lead to
persistent DNA breaks.
DISCUSSION
New drugs for African trypanosomiasis are needed, as current
drugs are old, often toxic, and have become increasingly ineffec-
tive due to resistance (4, 6–8). A few new compounds are now
proceeding to clinical test stages (7, 42), but trypanosomiasis is a
complex set of diseases involving various pathogenic species,
hosts, anddisease stages forwhich a single panacea is unlikely to be
developed. Using a rational drug design approach, we took advan-
tage of the multiple high-affinity nucleobase uptake transporters
in theT. brucei parasite for selective delivery of toxic cargo into the
parasite.We synthesized a series of methyltriazenyl purine (MTP)
prodrugs and evaluated their antitrypanosomal activities. We
identified MTP derivative 1 with high antitrypanosomal potency
and curative efficacy in an animal model of acute trypanosomiasis
and investigated its mode of action.
Based on our study, we suggest a working model for the para-
site-selective toxicity displayed by compound 1 (Fig. 5). MTP 1
was designed to be taken up by active transport via the trypano-
somal purine nucleobase transporters H2 and H3 (18). Indeed,
compound 1 (and the derivative compound 2) revealed a signifi-
cantly higher affinity for the trypanosomal H2 over the human
FNT1 and displayed lower trypanocidal activity in medium con-
taining high concentrations of hypoxanthine than the same con-
centration of inosine, consistent with competition at the level of
uptake. Retention of potency against a drug-resistant line lacking
the TbAT1/P2 aminopurine transporter gene indicated that this
activity is not primarily involved in the uptake of MTPs, and
cross-resistance with diamidine drugs is not likely to arise. This
was in agreement with previous reports that TbAT1/P2 does not
transport 6-oxopurines (43) and poorly tolerates even small sub-
stitutions on position 2 of aminopurines (44). Given the hydro-
philic nature of compound 1, passive diffusion across any cell
membrane, whether parasite or mammalian, is not likely to occur
at a significant rate, which may, at least in part, account for the
observed absence of mutagenicity, hepatotoxicity, and cytotoxic-
ity againstmammalian cells.We conclude that uptake through the
T. brucei nucleobase transporters at least contributes to the selec-
tive cytotoxic activities of the MTPs reported here.
A high threshold concentration of SN1-type alkylating drugs
seems to be required for inducing cell death in cancer cells, as
implied by the minimum of 6,000 O6-methyl guanine lesions per
cell (45, 46). The number of DNA lesions in trypanosomes leading
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to irrecoverable cell death remains to be determined, but active
transport by purine transporters likely facilitates a high intra-
cellular concentration of the SN1-type alkylator compound 1.
In contrast, the high lethal threshold value is not likely to be
attained inmammalian cells due to the requirement forMTP to
be transported into the cytoplasm of the cell. Even if the MTPs
were efficient substrates for the human facilitative nucleobase
transporter (hFNT), this mechanism is nonconcentrative and
merely facilitates the passive bidirectional passage across the
plasma membrane (47). The observation that treatment with
compound 1 induces double-strand breaks in T. brucei but not
in human cells is consistent with its proposed mechanism of
action and selectivity.
In fact, DNA damagemay be a particular vulnerability of the try-
panosome. Several drugs currently used in the clinic (nifurtimox-
eflornithine combination therapy [NECT]) or in clinical trials (fex-
inidazole) againstHAT (48) and leishmaniasis (49) have been shown
to cause enhanced DNA lesions in trypanosomes. Eflornithine (di-
fluoromethylornithine [DFMO]) causes a dramatic increase in de-
carboxylated S-adenosylmethionine (dSAM) and S-adenosylme-
thionine (SAM) in T. brucei in vivo (50), and these methylating
metabolites may contribute to DNA alkylations (51). DFMO-in-
duced depletion of trypanothione and polyamines may further po-
tentiate the methylating activity of SAM by lowering levels of com-
peting nucleophiles, while reduced levels of polyamines may make
nucleic acidsmore susceptible tomethylation (52).Thenitro-hetero-
cyclic prodrugs nifurtimox and fexinidazole (53) require bioreduc-
tive activation, which generates cytotoxicmetabolites (54) that cause
DNA (55), lipid, and protein damage (56).
DNA alkylation was proposed 2 decades ago as an antit-
rypanosomal strategy (57) but has since been neglected, as the
alkylating species developed at that time, 1,2-bis(methylsulfonyl)-
1-methylhydrazine, lacked parasite selectivity (51).We have revis-
ited DNA alkylation as antiparasitic chemotherapy by exploiting
the purine uptake system of the parasite for targeted delivery of a
DNA-targeting toxin into the parasite and by optimizing the
prodrug hydrolysis rate. We have shown that the MTP lead
compound 1 acts on target, causing DNA strand breaks in T.
brucei but not in human HEK cells. MTP compound 1 is well
tolerated (up to 10 50mg/kg i.p. daily without any overt adverse
effects) and cures acute trypanosomiasis in mice while showing a
high cure rate in acute T. brucei rhodesiense infection in vivo, su-
perior to that of pentamidine (58). The observed absence of geno-
toxicity, hepatotoxicity, and cytotoxicity against mammalian cells
revitalizes the idea of pursuing DNA alkylators as a safe chemo-
therapeutic option for the treatment of human or veterinary
trypanosomiasis.
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